Sort by
Items per page

Send to

Choose Destination

Best matches for Clément-Duchêne C[au]:

Search results

Items: 37


ASO Author Reflections: Survival Impact of N2 in Non-small Cell Lung Cancer.

Clément-Duchêne C.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):944-945. doi: 10.1245/s10434-018-6779-9. Epub 2018 Sep 22. No abstract available.


Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clément-Duchêne C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazières J, Besse B, Girard N.

J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.


A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Gubens MA, Chuang JC, Akerley W, Langer CJ, Clément-Duchêne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA.

J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.


Survival Impact of Stations of Pathological Lymph Nodes in N2 Non-small Cell Lung Cancer in a French Hospital.

Clément-Duchêne C, Luc A, Casse JM, Vignaud JM, Lacomme S, Anne V, Siat J, Ménard O, Martinet Y.

Ann Surg Oncol. 2018 May;25(5):1262-1268. doi: 10.1245/s10434-018-6373-1. Epub 2018 Feb 14.


Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.

Renaud S, Seitlinger J, Guerrera F, Reeb J, Beau-Faller M, Voegeli AC, Siat J, Clément-Duchêne C, Tiotiu A, Santelmo N, Costardi L, Ruffini E, Falcoz PE, Vignaud JM, Massard G.

Ann Surg Oncol. 2018 Apr;25(4):1069-1078. doi: 10.1245/s10434-018-6347-3. Epub 2018 Jan 23.


[Prophylactic radiotherapy in a single fraction of 10Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study].

Carette H, Faivre JC, Salleron J, Baumann AS, Uwer L, Clément-Duchêne C, Vignaud JM, Petit I, Siat J, Tiotiu A, Beckendorf V.

Cancer Radiother. 2017 Dec;21(8):774-783. doi: 10.1016/j.canrad.2017.06.011. Epub 2017 Nov 11. French.


Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N.

J Thorac Oncol. 2017 Nov;12(11):1715-1722. doi: 10.1016/j.jtho.2017.07.023. Epub 2017 Jul 31.


[Complementary and alternative medicine use by lung cancer patients].

Rossanaly Vasram R, Zysman M, Ribeiro Baptista B, Ederle C, Nguyen-Thi PL, Clement-Duchene C, Martinet Y.

Rev Pneumol Clin. 2017 Sep;73(4):172-179. doi: 10.1016/j.pneumo.2017.04.002. Epub 2017 Jul 26. French.


[Hypofractionated stereotactic radiotherapy for brain metastasis: Benefit of additional whole brain radiotherapy?]

Royer P, Salleron J, Vogin G, Taillandier L, Clément-Duchêne C, Klein O, Faivre JC, Peiffert D, Bernier V.

Cancer Radiother. 2017 Dec;21(8):731-740. doi: 10.1016/j.canrad.2017.02.005. Epub 2017 Jul 12. French.


[Malignant rhabdoid tumor of the lung].

Zysman M, Clement-Duchene C, Bastien C, Vaillant P, Martinet Y.

Rev Mal Respir. 2016 Nov;33(9):808-811. doi: 10.1016/j.rmr.2015.09.011. Epub 2016 Aug 29. French.


Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in France.

Rivoisy C, Besse B, Girard N, Lioger B, Viallard JF, Lega JC, Rullier P, Perlat A, Lerouge D, Clement-Duchene C, Ebbo M, Bosseray A, Godeau B, Lambotte O.

J Thorac Oncol. 2016 Mar;11(3):391-9. doi: 10.1016/j.jtho.2015.11.012. Epub 2016 Jan 4.


Survival among Never-Smokers with Lung Cancer in the Cancer Care Outcomes Research and Surveillance Study.

Clément-Duchêne C, Stock S, Xu X, Chang ET, Gomez SL, West DW, Wakelee HA, Gould MK.

Ann Am Thorac Soc. 2016 Jan;13(1):58-66. doi: 10.1513/AnnalsATS.201504-241OC.


Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.


[Management of chemotherapy-induced anemia in lung cancer].

Tiotiu A, Clément-Duchêne C, Martinet Y.

Rev Mal Respir. 2015 Oct;32(8):809-21. doi: 10.1016/j.rmr.2014.10.734. Epub 2015 Jun 4. Review. French.


Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.


Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients' survival.

Lemonnier I, Guillemin F, Arveux P, Clément-Duchêne C, Velten M, Woronoff-Lemsi MC, Jolly D, Baumann C.

Health Qual Life Outcomes. 2014 May 15;12:73. doi: 10.1186/1477-7525-12-73.


[Evaluation of requests for a second medical opinion by patients with lung cancer].

Zysman M, Clément-Duchène C, Nguyen-Thi PL, Carnin C, Martinet Y.

Rev Mal Respir. 2014 May;31(5):412-20. doi: 10.1016/j.rmr.2013.09.004. Epub 2013 Oct 18. French.


Is there a relationship between the presence of lung mucosa preinvasive lesions and lung cancer incidence? Influence of tobacco consumption.

Clément-Duchêne C, Alla F, Gauchotte G, Marie B, Carnin C, Menard O, Vignaud JM, Martinet Y.

Lung Cancer. 2014 May;84(2):134-8. doi: 10.1016/j.lungcan.2014.02.003. Epub 2014 Feb 16.


CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.

Elakoum R, Gauchotte G, Oussalah A, Wissler MP, Clément-Duchêne C, Vignaud JM, Guéant JL, Namour F.

Biochimie. 2014 Feb;97:210-8. doi: 10.1016/j.biochi.2013.10.021. Epub 2013 Nov 6.


[Primary lateral sclerosis and lung adenocarcinoma].

Martinez L, Lamaze R, Clément-Duchêne C.

Rev Mal Respir. 2013 Mar;30(3):227-30. doi: 10.1016/j.rmr.2012.12.003. Epub 2013 Feb 6. French.


Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.

Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF.

Lung Cancer. 2013 May;80(2):185-90. doi: 10.1016/j.lungcan.2013.01.008. Epub 2013 Feb 21.


A combination of smears and cell block preparations provides high diagnostic accuracy for endobronchial ultrasound-guided transbronchial needle aspiration.

Gauchotte G, Vignaud JM, Ménard O, Wissler MP, Martinet Y, Siat J, Paris C, Clément-Duchêne C.

Virchows Arch. 2012 Nov;461(5):505-12. doi: 10.1007/s00428-012-1296-x. Epub 2012 Aug 16.


A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.

Clément-Duchêne C, Natale RB, Jahan T, Krupitskaya Y, Osarogiagbon R, Sanborn RE, Bernstein ED, Dudek AZ, Latz JE, Shi P, Wakelee HA.

Lung Cancer. 2012 Oct;78(1):57-62. doi: 10.1016/j.lungcan.2012.06.003. Epub 2012 Jul 17.


Occupational risk factors have to be considered in the definition of high-risk lung cancer populations.

Wild P, Gonzalez M, Bourgkard E, Courouble N, Clément-Duchêne C, Martinet Y, Févotte J, Paris C.

Br J Cancer. 2012 Mar 27;106(7):1346-52. doi: 10.1038/bjc.2012.75.


[Anti-angiogenic agents in the treatment of lung cancer: indications and toxicities].

Clément-Duchêne C, Godbert B, Martinet Y.

Rev Mal Respir. 2012 Feb;29(2):161-77. doi: 10.1016/j.rmr.2011.06.017. Epub 2012 Jan 4. Review. French.


Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.

Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA.

Cancer Invest. 2012 Mar;30(3):231-5. doi: 10.3109/07357907.2012.656862.


Smoking, occupational risk factors, and bronchial tumor location: a possible impact for lung cancer computed tomography scan screening.

Gonzalez M, Vignaud JM, Clement-Duchene C, Luc A, Wild P, Bertrand O, Thiberville L, Martinet Y, Benichou J, Paris C.

J Thorac Oncol. 2012 Jan;7(1):128-36. doi: 10.1097/JTO.0b013e318233d7a6.


[Diagnostic accuracy of endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal lymph nodes].

Gauchotte G, Wissler MP, Bressenot A, Clément-Duchêne C, Marie B, Ménard O, Vignaud JM.

Ann Pathol. 2011 Jun;31(3):142-51. doi: 10.1016/j.annpat.2011.02.007. Epub 2011 May 18. French.


Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked.

Gomez SL, Chang ET, Shema SJ, Fish K, Sison JD, Reynolds P, Clément-Duchêne C, Wrensch MR, Wiencke JL, Wakelee HA.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):545-54. doi: 10.1158/1055-9965.EPI-10-0965. Epub 2011 Jan 14.


A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.

Clément-Duchêne C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA.

J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c.


[Do all cryptogenic organizing pneumonias require lung biopsy and steroid treatment?].

Godbert B, Clement-Duchêne C, Regent D, Martinet Y.

Rev Mal Respir. 2010 May;27(5):509-14. doi: 10.1016/j.rmr.2010.03.016. French.


How accurate are physicians in the prediction of patient survival in advanced lung cancer?

Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y.

Oncologist. 2010;15(7):782-9. doi: 10.1634/theoncologist.2009-0149. Epub 2010 Jun 17.


[Protocols for lung cancer screening: Limitations, and consequences].

Clément-Duchêne C, Guillemin F, Paris C, Régent D, Martinet Y.

Rev Mal Respir. 2010 Apr;27(4):314-28. doi: 10.1016/j.rmr.2009.11.012. Epub 2010 Feb 12. Review. French.


Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review.

Clément-Duchêne C, Wakelee H.

J Thorac Oncol. 2010 Jan;5(1):129-39. doi: 10.1097/JTO.0b013e3181c59a60. Review.


Relationships between lung adenocarcinoma and gender, age, smoking and occupational risk factors: A case-case study.

Paris C, Clement-Duchene C, Vignaud JM, Gislard A, Stoufflet A, Bertrand O, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P.

Lung Cancer. 2010 May;68(2):146-53. doi: 10.1016/j.lungcan.2009.06.007. Epub 2009 Jul 7.


Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?

Wakelee HA, Merritt R, Clément-Duchêne C.

Oncology (Williston Park). 2009 May;23(6):527, 532. No abstract available.


Characteristics of never smoker lung cancer including environmental and occupational risk factors.

Clément-Duchêne C, Vignaud JM, Stoufflet A, Bertrand O, Gislard A, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P, Paris C.

Lung Cancer. 2010 Feb;67(2):144-50. doi: 10.1016/j.lungcan.2009.04.005. Epub 2009 May 21.


Supplemental Content

Loading ...
Support Center